Last reviewed · How we verify
Diflucan (fluconazole)
Diflucan (fluconazole) is a Triazole antifungal Small molecule drug developed by Pfizer. It is currently FDA-approved for Candidiasis (oropharyngeal, esophageal, vaginal, and systemic), Cryptococcal meningitis, Coccidioidomycosis.
Fluconazole inhibits fungal cytochrome P450-dependent lanosterol 14α-demethylase, disrupting ergosterol synthesis and compromising fungal cell membrane integrity.
Fluconazole inhibits fungal cytochrome P450-dependent lanosterol 14α-demethylase, disrupting ergosterol synthesis and compromising fungal cell membrane integrity. Used for Candidiasis (oropharyngeal, esophageal, vaginal, and systemic), Cryptococcal meningitis, Coccidioidomycosis.
At a glance
| Generic name | Diflucan (fluconazole) |
|---|---|
| Sponsor | Pfizer |
| Drug class | Triazole antifungal |
| Target | Fungal cytochrome P450 14α-demethylase (CYP51) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
By blocking the conversion of lanosterol to ergosterol, a critical sterol in fungal cell membranes, fluconazole causes membrane destabilization and leakage of cellular contents, leading to fungal cell death. This mechanism is selective for fungal cells because they rely on ergosterol, whereas human cells use cholesterol instead. Fluconazole is a triazole antifungal that acts as a fungistatic agent, halting fungal growth and allowing the immune system to clear the infection.
Approved indications
- Candidiasis (oropharyngeal, esophageal, vaginal, and systemic)
- Cryptococcal meningitis
- Coccidioidomycosis
- Onychomycosis
- Pityriasis versicolor
- Fungal prophylaxis in immunocompromised patients
Common side effects
- Headache
- Nausea
- Abdominal pain
- Diarrhea
- Rash
- Elevated liver enzymes
- Stevens-Johnson syndrome
Key clinical trials
- A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1) (PHASE1, PHASE2)
- A Study of Olomorasib (LY3537982) in Healthy Participants (PHASE1)
- The LISA (Lactoferrin InStead of Antibiotics/Antifungals) Feasibility Study (NA)
- A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis. (PHASE3)
- A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation (PHASE1, PHASE2)
- Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial (PHASE3)
- A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation (PHASE2)
- A Study to Learn How Fluconazole, Carbamazepine and Itraconazole Affect How the Body Processes ASP3082 in Healthy Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Diflucan (fluconazole) CI brief — competitive landscape report
- Diflucan (fluconazole) updates RSS · CI watch RSS
- Pfizer portfolio CI
Frequently asked questions about Diflucan (fluconazole)
What is Diflucan (fluconazole)?
How does Diflucan (fluconazole) work?
What is Diflucan (fluconazole) used for?
Who makes Diflucan (fluconazole)?
What drug class is Diflucan (fluconazole) in?
What development phase is Diflucan (fluconazole) in?
What are the side effects of Diflucan (fluconazole)?
What does Diflucan (fluconazole) target?
Related
- Drug class: All Triazole antifungal drugs
- Target: All drugs targeting Fungal cytochrome P450 14α-demethylase (CYP51)
- Manufacturer: Pfizer — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Candidiasis (oropharyngeal, esophageal, vaginal, and systemic)
- Indication: Drugs for Cryptococcal meningitis
- Indication: Drugs for Coccidioidomycosis
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing